Stoke Therapeutics, Inc. (STOK) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1240513,
    "name": "Stoke Therapeutics, Inc.",
    "stock_name": "Stoke Therapeutics, Inc.",
    "full_name": "Stoke Therapeutics, Inc.",
    "name_url": "stocks-analysis/stoke-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "30.87",
    "chg": -0.18,
    "chgp": "-0.58%",
    "dir": -1,
    "prev_price": "31.05",
    "mcapval": "1,205.00",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US86150R1077",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "1.21 M",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/stoke-therapeutics-inc-1240513-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Stoke Therapeutics Hits Day Low of $24.50 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/stoke-therapeutics-hits-day-low-of-2450-amid-price-pressure-3671579",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/StokeTherapeuti_priceRelatedfactors_3671579.png",
        "date": "2025-11-04 18:32:23",
        "description": "Stoke Therapeutics, Inc. saw a notable stock decline today, despite a strong year-long performance with a 102.95% increase. The company reported positive financial metrics, including significant operating cash flow and net sales, while maintaining full institutional ownership. However, it faces challenges with a low return on equity."
      },
      {
        "title": "Is Stoke Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-stoke-therapeutics-inc-overvalued-or-undervalued-3637942",
        "imagepath": "",
        "date": "2025-10-21 12:12:03",
        "description": "As of 17 October 2025, the valuation grade for Stoke Therapeutics, Inc. has moved from fair to expensive, indicating that the company is overvalued. Key valuation ratios include a P/E ratio of 12, an EV to EBITDA of 5.94, and a PEG ratio of 0.09, which suggest that while the company has some attractive growth potential, it is currently priced higher than its fundamentals warrant.\n\nIn comparison to peers, Stoke Therapeutics has a significantly higher P/E ratio of 22.96 compared to CorMedix, Inc. at 18.60, which is considered very attractive, and Taysha Gene Therapies, Inc. which is deemed risky with a negative P/E. This disparity highlights that Stoke is trading at a premium relative to its more favorably valued peers. Additionally, Stoke Therapeutics has outperformed the S&P 500 over multiple periods, with a year-to-date return of 203.99% compared to the S&P 500's 13.30%, but this strong performance does no..."
      },
      {
        "title": "Stoke Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/stoke-therapeutics-valuation-grade-changes-from-fair-to-expensive-amid-strong-stock-performance-3641085",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/StokeTherapeuti_valuationdot_3641085.png",
        "date": "2025-10-20 17:21:39",
        "description": "Stoke Therapeutics, Inc. has recently adjusted its valuation, with a P/E ratio of 12 and a low PEG ratio of 0.09, indicating unique growth potential. The company has delivered impressive returns, outperforming the S&P 500 significantly, while its competitive landscape reveals varied financial health among peers."
      },
      {
        "title": "Is Stoke Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-stoke-therapeutics-inc-overvalued-or-undervalued-3634812",
        "imagepath": "",
        "date": "2025-10-20 12:29:18",
        "description": "As of 17 October 2025, the valuation grade for Stoke Therapeutics, Inc. has moved from fair to expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 12, a Price to Book Value of 1.74, and an EV to EBITDA ratio of 5.94, which are relatively low compared to its peers. For instance, CorMedix, Inc. has a P/E of 18.60, while Taysha Gene Therapies, Inc. shows a negative P/E, highlighting the varying valuations within the sector.\n\nDespite the company's strong recent performance, with a year-to-date return of 203.99% compared to the S&P 500's 13.30%, the overall valuation metrics suggest that Stoke Therapeutics is not a bargain at its current price. The significant disparity in valuation ratios compared to peers reinforces the conclusion that the stock is overvalued...."
      },
      {
        "title": "Is Stoke Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-stoke-therapeutics-inc-overvalued-or-undervalued-3632350",
        "imagepath": "",
        "date": "2025-10-19 12:06:38",
        "description": "As of 17 October 2025, the valuation grade for Stoke Therapeutics, Inc. has moved from fair to expensive, indicating that the company is overvalued. Key valuation ratios reveal a P/E ratio of 12, an EV to EBITDA of 5.94, and a PEG ratio of 0.09, which suggest that despite some attractive metrics, the overall valuation does not justify the current price levels.\n\nIn comparison to peers, Stoke Therapeutics has a higher P/E ratio than CorMedix, Inc., which stands at 18.60 and is considered very attractive, while Taysha Gene Therapies, Inc. is in a risky position with a negative P/E. The recent stock performance shows that Stoke Therapeutics has significantly outperformed the S&P 500, with a year-to-date return of 203.99% compared to the index's 13.30%, reinforcing the notion that the stock may be overvalued given its current price relative to its earnings potential...."
      },
      {
        "title": "Stoke Therapeutics Hits New 52-Week High of $37.67, Up 139%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/stoke-therapeutics-hits-new-52-week-high-of-3767-up-139-3626660",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/StokeTherapeuti_priceRelatedfactors_3626660.png",
        "date": "2025-10-16 18:26:53",
        "description": "Stoke Therapeutics, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector with a one-year growth of 139.09%. The company, with a market capitalization of USD 1,205 million, showcases effective management and a solid balance sheet, highlighting its competitive position."
      },
      {
        "title": "Stoke Therapeutics Hits Day High with 15.16% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/stoke-therapeutics-hits-day-high-with-1516-surge-in-stock-price-3622893",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/StokeTherapeuti_priceRelatedfactors_3622893.png",
        "date": "2025-10-15 17:40:20",
        "description": "Stoke Therapeutics, Inc. saw a notable increase in its stock price on October 14, 2025, reaching an intraday high. The company has achieved a remarkable annual return and strong year-to-date performance, reporting significant net profits and sales, while maintaining high institutional holdings and consistent positive results over recent quarters."
      },
      {
        "title": "Stoke Therapeutics Hits New 52-Week High of $35.08, Up 134.65%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/stoke-therapeutics-hits-new-52-week-high-of-3508-up-13465-3622832",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/StokeTherapeuti_priceRelatedfactors_3622832.png",
        "date": "2025-10-15 17:09:29",
        "description": "Stoke Therapeutics, Inc. has achieved a new 52-week high of USD 35.08, reflecting a significant increase in stock performance over the past year. With a market capitalization of USD 1,205 million, the company showcases strong financial metrics and a solid position in the biotechnology sector."
      },
      {
        "title": "Stoke Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/stoke-therapeutics-changes-valuation-grade-from-fair-to-expensive-amid-price-increase-3617502",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/StokeTherapeuti_valuationdot_3617502.png",
        "date": "2025-10-13 16:01:10",
        "description": "Stoke Therapeutics, Inc. has recently adjusted its valuation, with its stock price reflecting a modest increase. Over the past year, the company has achieved a notable return, significantly surpassing the S&P 500. Key financial metrics indicate a mixed performance compared to industry peers, highlighting the competitive landscape."
      }
    ],
    "total": 21,
    "sid": "1240513",
    "stock_news_url": "https://www.marketsmojo.com/news/stoke-therapeutics-inc-1240513"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Stoke Therapeutics Hits Day Low of $24.50 Amid Price Pressure

2025-11-04 18:32:23

Stoke Therapeutics, Inc. saw a notable stock decline today, despite a strong year-long performance with a 102.95% increase. The company reported positive financial metrics, including significant operating cash flow and net sales, while maintaining full institutional ownership. However, it faces challenges with a low return on equity.

Is Stoke Therapeutics, Inc. overvalued or undervalued?

2025-10-21 12:12:03

As of 17 October 2025, the valuation grade for Stoke Therapeutics, Inc. has moved from fair to expensive, indicating that the company is overvalued. Key valuation ratios include a P/E ratio of 12, an EV to EBITDA of 5.94, and a PEG ratio of 0.09, which suggest that while the company has some attractive growth potential, it is currently priced higher than its fundamentals warrant. In comparison to peers, Stoke Therapeutics has a significantly higher P/E ratio of 22.96 compared to CorMedix, Inc. at 18.60, which is considered very attractive, and Taysha Gene Therapies, Inc. which is deemed risky with a negative P/E. This disparity highlights that Stoke is trading at a premium relative to its more favorably valued peers. Additionally, Stoke Therapeutics has outperformed the S&P 500 over multiple periods, with a year-to-date return of 203.99% compared to the S&P 500's 13.30%, but this strong performance does no...

Stoke Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics

2025-10-20 17:21:39

Stoke Therapeutics, Inc. has recently adjusted its valuation, with a P/E ratio of 12 and a low PEG ratio of 0.09, indicating unique growth potential. The company has delivered impressive returns, outperforming the S&P 500 significantly, while its competitive landscape reveals varied financial health among peers.

Is Stoke Therapeutics, Inc. overvalued or undervalued?

2025-10-20 12:29:18

As of 17 October 2025, the valuation grade for Stoke Therapeutics, Inc. has moved from fair to expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 12, a Price to Book Value of 1.74, and an EV to EBITDA ratio of 5.94, which are relatively low compared to its peers. For instance, CorMedix, Inc. has a P/E of 18.60, while Taysha Gene Therapies, Inc. shows a negative P/E, highlighting the varying valuations within the sector. Despite the company's strong recent performance, with a year-to-date return of 203.99% compared to the S&P 500's 13.30%, the overall valuation metrics suggest that Stoke Therapeutics is not a bargain at its current price. The significant disparity in valuation ratios compared to peers reinforces the conclusion that the stock is overvalued....

Is Stoke Therapeutics, Inc. overvalued or undervalued?

2025-10-19 12:06:38

As of 17 October 2025, the valuation grade for Stoke Therapeutics, Inc. has moved from fair to expensive, indicating that the company is overvalued. Key valuation ratios reveal a P/E ratio of 12, an EV to EBITDA of 5.94, and a PEG ratio of 0.09, which suggest that despite some attractive metrics, the overall valuation does not justify the current price levels. In comparison to peers, Stoke Therapeutics has a higher P/E ratio than CorMedix, Inc., which stands at 18.60 and is considered very attractive, while Taysha Gene Therapies, Inc. is in a risky position with a negative P/E. The recent stock performance shows that Stoke Therapeutics has significantly outperformed the S&P 500, with a year-to-date return of 203.99% compared to the index's 13.30%, reinforcing the notion that the stock may be overvalued given its current price relative to its earnings potential....

Stoke Therapeutics Hits New 52-Week High of $37.67, Up 139%

2025-10-16 18:26:53

Stoke Therapeutics, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector with a one-year growth of 139.09%. The company, with a market capitalization of USD 1,205 million, showcases effective management and a solid balance sheet, highlighting its competitive position.

Stoke Therapeutics Hits Day High with 15.16% Surge in Stock Price

2025-10-15 17:40:20

Stoke Therapeutics, Inc. saw a notable increase in its stock price on October 14, 2025, reaching an intraday high. The company has achieved a remarkable annual return and strong year-to-date performance, reporting significant net profits and sales, while maintaining high institutional holdings and consistent positive results over recent quarters.

Stoke Therapeutics Hits New 52-Week High of $35.08, Up 134.65%

2025-10-15 17:09:29

Stoke Therapeutics, Inc. has achieved a new 52-week high of USD 35.08, reflecting a significant increase in stock performance over the past year. With a market capitalization of USD 1,205 million, the company showcases strong financial metrics and a solid position in the biotechnology sector.

Stoke Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance

2025-10-13 16:01:10

Stoke Therapeutics, Inc. has recently adjusted its valuation, with its stock price reflecting a modest increase. Over the past year, the company has achieved a notable return, significantly surpassing the S&P 500. Key financial metrics indicate a mixed performance compared to industry peers, highlighting the competitive landscape.

View All News